Furthermore, A. muciniphila administration was proved to boost the therapeutic effects in antibiotic-exposed mice receiving anti-PD1 therapy, and Bifidobacterium supplement largely reversed the anti-PD-L1 resistant status in melanoma-bearing mice, indicating its potential role in assisting PD1/PD-L1 blockade efficacy (20, 22). The gene discussed is CD274; the disease is melanoma.